Overview

  • Product nameAnti-CPT2 antibody
    See all CPT2 primary antibodies
  • Description
    Mouse monoclonal to CPT2
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Recombinant Fragment
    Predicted to work with: Human
  • Immunogen

    Recombinant fragment: WFDKSFNLII AKDGSTAIHF EHSWGDGVAV LRFFNEVFKD STQTPAVTPQ SQPATTDSTV TVQKLNFELT DALKTGITAA KEKFDATMKT LTIDCVQFQR , corresponding to amino acids 351-451 of Human CPT2

Applications

Our Abpromise guarantee covers the use of ab54589 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notesWB: Use at a concentration of 1-5 µg/ml.

    This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • PathwayLipid metabolism; fatty acid beta-oxidation.
    • Involvement in diseaseDefects in CPT2 are the cause of carnitine palmitoyltransferase 2 deficiency (CPT2D) [MIM:255110, 600649]; also known as CPT-II deficiency or CPT2 deficiency. CPT2D is an autosomal recessive disorder characterized by recurrent myoglobinuria, episodes of muscle pain, stiffness, and rhabdomyolysis. These symptoms are triggered by prolonged exercise, fasting or viral infection and patients are usually young adults. In addition to this classical, late-onset, muscular type, a hepatic or hepatocardiomuscular form has been reported in infants. Clinical pictures in these children or neonates include hypoketotic hypoglycemia, liver dysfunction, cardiomyopathy and sudden death.
      Defects in CPT2 are the cause of carnitine palmitoyltransferase 2 deficiency, lethal neonatal (CPT2D-LN) [MIM:608836]; also known as lethal neonatal CPT-II deficiency. It is a lethal neonatal form of CPT2D. This rarely presentation is antenatal with cerebral periventricular cysts and cystic dysplastic kidneys. The clinical variability of the disease is likely attributed to the variable residual enzymatic activity.
    • Sequence similaritiesBelongs to the carnitine/choline acetyltransferase family.
    • Cellular localizationMitochondrion inner membrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • Carnitine O palmitoyltransferase 2 antibody
      • Carnitine O palmitoyltransferase 2 mitochondrial antibody
      • Carnitine O-palmitoyltransferase 2 antibody
      • Carnitine palmitoyltransferase 2 antibody
      • Carnitine palmitoyltransferase II antibody
      • CPT 1 antibody
      • CPT 2 antibody
      • CPT II antibody
      • CPT1 antibody
      • CPT2 antibody
      • CPT2_HUMAN antibody
      • CPTASE antibody
      • CPTII antibody
      • IIAE4 antibody
      • mitochondrial antibody
      see all

    Anti-CPT2 antibody images

    • Western blot against tagged recombinant protein immunogen using ab54589 CPT2 antibody at 1ug/ml. Predicted band size of immunogen is 37 kDa.

      This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.

    References for Anti-CPT2 antibody (ab54589)

    ab54589 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab54589.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"